BCM
SGMT icon

Bridgeway Capital Management’s Sagimet Biosciences SGMT Stock Holding History

Bridgeway Capital Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71M Sell
221,541
-78,100
-26% -$531K 0.03% 611
2026
Q1 		$1.57M Hold
299,641
– – 0.03% 592
2025
Q4 		$1.77M Hold
299,641
– – 0.04% 573
2025
Q3 		$2.06M Sell
299,641
-113,200
-27% -$918K 0.04% 545
2025
Q2 		$3.15M Buy
412,841
+288,341
+232% +$1.22M 0.07% 371
2025
Q1 		$406K Sell
124,500
-99,600
-44% -$418K 0.01% 781
2024
Q4 		$1.01M Buy
224,100
+85,800
+62% +$435K 0.02% 670
2024
Q3 		$383K Buy
138,300
+93,300
+207% +$288K 0.01% 924
2024
Q2 		$154K Hold
45,000
– – ﹤0.01% 1107
2024
Q1 		$244K Hold
45,000
– – 0.01% 1071
2023
Q4 		$244K Buy
+45,000
New +$212K 0.01% 1096

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Bridgeway Capital Management's SGMT Position: Q2 2026 in Review

Bridgeway Capital Management reduced its Sagimet Biosciences (SGMT) stake by 26% in Q2 2026, selling an estimated $531K and leaving 221,541 shares worth $1.71M. The position accounts for 0.03% of the portfolio, ranked #611.

Bridgeway Capital Management first reported a position in SGMT in Q4 2023 and has held it in 11 quarters since. The position peaked at $3.15M in Q2 2025. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Bridgeway Capital Management held 221,541 shares of Sagimet Biosciences worth $1.71M as of Q2 2026.
  • Bridgeway Capital Management sold 78,100 Sagimet Biosciences shares in Q2 2026, an estimated $531K.
  • Sagimet Biosciences made up 0.03% of Bridgeway Capital Management's portfolio in Q2 2026, its #611 holding.
  • Bridgeway Capital Management first reported a position in Sagimet Biosciences in Q4 2023 and has held it in 11 quarters since.
  • Bridgeway Capital Management's Sagimet Biosciences position peaked at $3.15M in Q2 2025.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.